CV

CapsoVision went public on July 2, 2025, at $5.00 per share. In November 2025, it submitted a Breakthrough Device Designation application to the FDA for its CapsoCam UGI system and reported a 19% revenue increase. In December 2025, the stock reached an all-time high of $14.42 and submitted a 510(k) application to the FDA for its AI-assisted module. In March 2026, the company completed a $14 million private placement and reported a 13% increase in fourth-quarter revenue, but operating expenses surged, leading to a negative earnings outlook and an 8.95% stock decline. Benchmark cut its price target to $10. In April 2026, CapsoVision filed a Form S-1. By May 8, 2026, the stock price was $7.12.